[HTML][HTML] IBD therapeutics: what is in the pipeline?
Inflammatory bowel disease (IBD) is an idiopathic long-term relapsing and remitting disorder
including ulcerative colitis and Crohn's disease. The aim of therapy is to induce and …
including ulcerative colitis and Crohn's disease. The aim of therapy is to induce and …
Evolving Experimental Platforms to Evaluate Ulcerative Colitis
TT Sharma, RR Rabizadeh, VS Prabhakar… - Advanced …, 2022 - Wiley Online Library
Ulcerative colitis (UC) is a multifactorial disease defined by chronic intestinal inflammation
with idiopathic origins. It has a predilection to affect the mucosal lining of the large intestines …
with idiopathic origins. It has a predilection to affect the mucosal lining of the large intestines …
[HTML][HTML] Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
J Salcedo, D Hill-McManus, C Hardern… - PharmacoEconomics …, 2024 - Springer
Background Today, there are many treatment options available for the management of
ulcerative colitis, creating challenges in selecting the most efficacious and cost-effective …
ulcerative colitis, creating challenges in selecting the most efficacious and cost-effective …
Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
S Ghosh, N Kathe, K Umashankar… - Crohn's & Colitis …, 2023 - academic.oup.com
Background Dose escalation of biologics may regain treatment response in patients with
ulcerative colitis (UC). However, dose escalation rates and associated outcomes and costs …
ulcerative colitis (UC). However, dose escalation rates and associated outcomes and costs …